Dietary fiber and sarcopenia risk in head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, mixed-methods study follows adults newly diagnosed with head and neck cancer for six months to examine the relationship between dietary fiber intake, short chain fatty acids, inflammation, and sarcopenia. Fiber intake will be assessed with the DHQIII and 24-hour recalls, while SCFAs will be measured in stool and inflammatory markers in blood samples. Muscle quantity and quality will be evaluated using CT scans, and muscle function will be tested with Timed Chair Stands and leg press power assessments. The study also explores patient perceptions and feasibility of increasing dietary fiber as part of cancer care. No intervention is assigned; the aim is to observe natural dietary patterns and their associations with catabolic factors during treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years of age
* Newly diagnosed with squamous cell carcinoma of the: paranasal sinuses, nasal cavity, oral cavity, tongue, larynx, pharynx \[i.e., nasopharynx, oropharynx, hypopharynx\]
* Meeting at least 60% of baseline energy needs
* Willingness to provide data prior to treatment
* Access to the internet
* Access to a home freezer
* Ability to do remote interview
* Access to a phone
* Willingness to avoid pre-, pro-, or synbiotics

Exclusion Criteria:

* Previously diagnosed or positive screen for a GI-related condition or eating disorder
* Able to complete bioelectrical impedance (stand unsupported, no pacemaker or limb amputation) and Timed Chair Stands
* Currently pregnant, planning to become pregnant, or breastfeeding
* Current or past 3-month antibiotic use

Where it's running

• Stephenson Cancer Center
  Oklahoma City, Oklahoma, United States Recruiting

Study contacts

• Study coordinator: Ashlea C Braun, PhD
• Email: ashlea-braun@ouhsc.edu
• Phone: 15672401582

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cough Skill Training to Help Head and Neck Cancer Patients Recover Voluntary Cough

  Researchers will test whether a handheld cough device-based training can help people with head and neck cancer improve their voluntary cough function.

  Recruiting Boston University Charles River Campus · Boston, Massachusetts · NCT07756684

• HMB Supplements to See If they Help Inflammation and Recovery After Head and Neck Cancer Surgery

  This study tests whether taking HMB before surgery can reduce inflammation and improve recovery for adults with head and neck cancer undergoing tumor removal.

  Recruiting Federal University of Minas Gerais · Belo Horizonte, Minas Gerais · NCT07675421

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Group program to promote post-traumatic growth for adults with breast, colorectal, or head and neck cancer in Greece

  This project will try a manualized, group-based ACT program to help Greek adults who finished chemotherapy for breast, colorectal, or head and neck cancer increase post-traumatic growth and quality of life.

  Recruiting Centre for Research and Technology Hellas · Thessaloniki · NCT07108517

• Telemedicine follow-up for early laryngeal cancer patients

  This study tests if follow-up care through Telemedicine is just as good as in-person visits for people with early laryngeal cancer, especially for those who live far from treatment centers.

  Recruiting University Medical Center Groningen · Groningen, Provincie Groningen · NCT06940505

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.